FL S1052

Creates the "Right to Try Act" allowing eligible patients with terminal conditions to access investigational drugs, biological products, or devices that have completed Phase 1 clinical trials but are not yet FDA-approved.

Establishes eligibility requirements including terminal illness certification by two physicians, consideration of all FDA-approved treatments, and written informed consent documenting risks and current treatment options.

Permits manufacturers to provide investigational treatments with or without compensation and allows patients to pay manufacturing costs, while health plans may optionally cover related expenses.

Protects physicians from license revocation or disciplinary action based solely on recommending investigational treatments to eligible patients.

Shields manufacturers and healthcare providers from civil liability for harm resulting from investigational treatments if they comply in good faith with the law and exercise reasonable care.